Company name
Akylox Therapeutics
Company profile
Akylox develops third generationPI3K inhibitors which combine multiple pharmacologies in a single, oral drug. Akylox is committed to fully harnessing the therapeutic potential of PI3K as an anti-tumor target by hitting the tumor harder while better sparing the patient’s other tissues. Akylox molecules target wild type and mutated tumors, providing superior efficacy independent of PAM pathway activation in the broadest patient population.
Date, time and room information
Tuesday, May 5, 13:00 - 13:15, room Singapore
Category
Emerging biotech company
Title of the presentation
Akylox – Harnessing the full potential of PI3Kα
Speaker information
| Name | Position | Institution |
|---|---|---|
| Alexander Flohr | Founder and CSO | Akylox Therapeutics |
